期刊文献+

含氟取代蝶啶类化合物的合成及结构表征

Synthesis and Characterization of Pteridine Derivatives with Fluorine-contained Groups
下载PDF
导出
摘要 目的合成一系列6-含氟烷氧基蝶啶类化合物并确证其化学结构。方法以3-氨基吡嗪-2-羧酸甲酯为起始底物,通过氨化、卤代、合环等六步反应合成一系列6-含氟烷氧基蝶啶类化合物。测定目标化合物的物理常数,并通过多种波谱分析技术(核磁共振氢谱、红外光谱、质谱)对其结构进行表征。结果以较高的产率(六步反应的总产率均大于24. 7%)制备多种6-含氟烷氧基蝶啶类化合物,经核磁共振氢谱及质谱等多种波谱手段确证为目标化合物。结论该方法操作简便,产率稳定,为未来的抗肿瘤活性实验提供有力的支持。 OBJECTIVE A series of 6-fluorine-contained alkoxyl pteridinesderivatives have been synthesized and their structures have been characterized. METHODS With methyl 3-aminopyrazine-2-carboxylate as the starting material,a series of 6-fluorine-contained alkoxyl pteridines derivatives have been yielded through 6 steps reaction involving amination,halogenationand cyclization etc.The physical constants of target compounds were determined,and their structures were characterized using various spectra techniques (1H-NMR,IR,MS). RESULTS 6-fluorine-contained alkoxyl pteridinesderivatives were prepared with a relatively higher yield (total yields for 6 steps reaction were higher than 24.7%),which were proved as target compounds byusing various spectra techniques such as 1H-NMR and MS etc. CONCLUSIO The synthetic route,with simple processes and good yields,substantially supports the antitumor study in the future.
作者 林锦 陈振东 王艰 许秀枝 李柱来 LIN Jin;CHEN Zhen-dong;WANG Jian;XU Xiu-zhi;LI Zhu-lai *(Department of Pharmaceutical Chemistry,School of Pharmacy,Fujian Medical University,Fuzhou 350122,China)
出处 《海峡药学》 2018年第10期84-86,共3页 Strait Pharmaceutical Journal
关键词 蝶啶 合成 表征 含氟 Pteridine Synthesis Characterization Fluorine-contained
  • 相关文献

参考文献1

二级参考文献39

  • 1Jimeno A,Hidalgo M.Multitargeted therapy:can promiscuity be praised in an era of political correctness?[J].Crit Rev Oncol Hematol,2006,59(2):150-158.
  • 2De Jonge MJ,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:all for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
  • 3Keith CT,Borisy AA,Stockwell BR.Multicomponent therapeutics for networked systems[J].Nat Rev Drug Discov,2005,4(1):71-78.
  • 4Arora A,Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(3):971-979.
  • 5Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
  • 6Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J].Cancer Res,2006,66(3):1630-1639.
  • 7Burris HA,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
  • 8Hanrahan EO,Heymach JV.Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer[J].Clin Cancer Res,2007,13(15):4617-4622.
  • 9Arnold AM,Seymour L,Smylie M,et al.Phase Ⅱ study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy:National Cancer Institute of Canada Clinical Trials Group Study BR.20[J].J Clin Oncol,2007,25(27):4278-4284.
  • 10Eskens FA,Mom CH,Planting AS,et al.A phase Ⅰ dose escalation study of BIBW 2992,an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumours[J].Br J Cancer,2008,98(1):80-85.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部